TSXV:ARCH
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • MetaMx™Brain Tumor Initiating Cell Targeting
      • MetaBlok™Blocking sepsis, inflammation and cancer metastasis
      • BORGPeptide Solid Surface Interface
      • Treatments for InflammationWidespread application for the treatment of chronic diseases.
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • Treatments for Inflammation
      • BORG Peptide
      • AB569 & Respiratory Pseudomonas
      • MetaBlok™ and MetaMx™
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Fundamentals

Investor Information

Find key information for investors – management and investor relations contact details, Auditor, Transfer Agent and SEDAR Profile.

Read more ...

Stock Performance

End of day (EOD) stock data, delayed. 

Read more ...

Subcategories

  • Press Releases

Recent News

March 27th 2018

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

Read More
March 21st 2018

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
545 King Street West
Toronto, Ontario
M5V 1M1 Canada
Copyright Arch BioPartners 2015. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Fundamentals
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • AB569
      • MetaMx™
      • MetaBlok™
      • BORG
      • Treatments for Inflammation
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • Treatments for Inflammation
      • BORG Peptide
      • AB569 & Respiratory Pseudomonas
      • MetaBlok™ and MetaMx™
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us